GRI Bio, Inc. (GRI)
GRI Stock Price Chart
Explore GRI Bio, Inc. interactive price chart. Choose custom timeframes to analyze GRI price movements and trends.
GRI Company Profile
Discover essential business fundamentals and corporate details for GRI Bio, Inc. (GRI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Feb 2021
Employees
4.00
Website
https://www.gribio.comCEO
W. Marc Hertz
Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Financial Timeline
Browse a chronological timeline of GRI Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$1.20.
Earnings released on 13 May 2026
EPS came in at -$1.61 falling short of the estimated -$0.91 by -76.92%.
Earnings released on 13 Mar 2026
EPS came in at -$13.25 surpassing the estimated -$29.27 by +54.73%.
Stock split effective on 26 Jan 2026
Shares were split 1 : 28 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2025
EPS came in at -$35.85 falling short of the estimated -$31.09 by -15.31%, while revenue for the quarter reached $6.33m .
Earnings released on 14 Aug 2025
EPS came in at -$1.31 matching the estimated -$1.31, while revenue for the quarter reached $22.54m .
Earnings released on 15 May 2025
EPS came in at -$5.80 falling short of the estimated -$4.11 by -41.12%.
Stock split effective on 24 Feb 2025
Shares were split 1 : 17 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Dec 2024
EPS came in at -$319.73 .
Earnings released on 14 Nov 2024
EPS came in at -$11.39 falling short of the estimated -$0.73 by -1.46k%.
Earnings released on 13 Aug 2024
EPS came in at -$83.67 .
Stock split effective on 18 Jun 2024
Shares were split 1 : 13 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at -$101.73 .
Stock split effective on 30 Jan 2024
Shares were split 1 : 7 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2023
EPS came in at -$4.32k .
Earnings released on 15 May 2023
EPS came in at -$8.25k .
Stock split effective on 24 Apr 2023
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 24 Feb 2023
EPS came in at -$0.10 surpassing the estimated -$13.46k by +100.00%.
Earnings released on 31 Dec 2022
EPS came in at -$1.29k .
Earnings released on 30 Sept 2022
EPS came in at -$221.59 surpassing the estimated -$11.60k by +98.09%.
Earnings released on 30 Jun 2022
EPS came in at -$259.68 surpassing the estimated -$10.67k by +97.57%.
Earnings released on 31 Mar 2022
EPS came in at -$2.96k falling short of the estimated -$46.20 by -6.30k%.
Earnings released on 31 Dec 2021
EPS came in at -$3.47k .
Earnings released on 30 Sept 2021
EPS came in at -$1.41k .
GRI Stock Performance
Access detailed GRI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
